Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass

Ítems similars

• Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
  per: Frey, Reiner, et al.
  Publicat: (2011)
• Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
  per: Scheerans, Christian, et al.
  Publicat: (2011)
• Pharmacological activation of soluble guanylate cyclase activator protects the heart against isoproterenol-induced myocardial ischemia in rats
  per: Korkmaz, Sevil, et al.
  Publicat: (2009)
• The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ Systems
  per: Vandendriessche, Benjamin, et al.
  Publicat: (2013)
• The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
  per: Vandendriessche, Benjamin, et al.
  Publicat: (2013)